Strategies for Diagnosis and Treatment of Adult ADHD in Primary Care
Psychiatry
Curriculum:
Strategies for Diagnosis and Treatment of Adult ADHD in Primary Care
Strategies for Diagnosis and Treatment of Adult ADHD in Primary Care
Credits:
1 AANP Contact Hours 1 AMA PRA Category 1 Credit(s) ™
1 AANP Contact Hours 1 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 22, 2016
December 22, 2016
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Primary Care MD/DO; and NPs/PAs and other clinicians managing adult patients with ADHD.
Relevant Terms:
Attention deficit hyperactivity disorder; cormorbidities; mood disorders; anxiety disorders
Gregg Mattingly, MD
Gregg Mattingly, MD Associate Clinical Professor Department of Psychiatry Washington University School of Medicine St. Louis, MO
Bio
Gregory W. Mattingly, MD currently is an Associate Clinical Professor and Psychopharmacology Instructor in the Department of Psychiatry at the Washington University School of Medicine in St. Louis and President of the Midwest Research Group.Dr. Mattingly earned his undergraduate degree in chemical engineering at the University of Missouri-Rolla in Rolla, Mo. He earned his medical degree at Washington University School of Medicine in St. Louis where he received a Fullbright Scholarship. He completed his psychiatry residency at Washington University School of Medicine in St. Louis. He is board certified in both psychiatry and neurology, with a subspecialty in adolescent psychiatry and is a diplomate of the National Board of Medical Examiners. Dr Mattingly has received numerous awards and distinctions including the Academy of Child and Adolescent Psychiatry National Leadership Award, the Upjohn Neuropsychiatry Research Award, and the Southern Psychiatric Association Research Award.
Dr. Mattingly has been a principal investigator in 300 clinical trials, as well as an invited presenter at numerous medical conferences, both nationally and internationally. Dr. Mattingly’s work has been published in The Journal of Neuropsychiatry and Clinical Neurosciences., The Journal of Clinical Psychiatry, Current Psychiatry, CNSs Spectrums and Postgraduate Medicine.
| 1. | Describe ADHD symptom profiles and common presentations in a primary care setting | 2. | Identify risks for coexisting disorders in adult patients with ADHD with emphasis on anxiety disorders, mood disorders, and substance use/abuse disorders |
| 3. | Implement appropriate pharmacologic treatment for adults diagnosed with ADHD designed to improve compliance, minimize side effects and maximize outcomes in a busy primary care setting | 4. | Use adult ADHD assessment and treatment tools for assessment, treatment and follow-up monitoring |
| 1. | Describe ADHD symptom profiles and common presentations in a primary care setting |
| 2. | Identify risks for coexisting disorders in adult patients with ADHD with emphasis on anxiety disorders, mood disorders, and substance use/abuse disorders |
| 3. | Implement appropriate pharmacologic treatment for adults diagnosed with ADHD designed to improve compliance, minimize side effects and maximize outcomes in a busy primary care setting |
| 4. | Use adult ADHD assessment and treatment tools for assessment, treatment and follow-up monitoring |
Planning Committee 
Gregg Sherman, MD
National Association for Continuing Education
Plantation, FL
Harvey C. Parker, Ph.D., CCMEP
National Association for Continuing Education
Plantation, FL
National Association for Continuing Education
Plantation, FL
Joshua Kilbridge, President
Kilbridge Associates
San Francisco, CA
Kilbridge Associates
San Francisco, CA
PROGRAM OVERVIEW:
While once thought of as a childhood disorder that primarily affected “disruptive” boys, ADHD is now known to persist into adulthood in approximately 60% of cases with an overall prevalence of 3-4% of US adults. Unlike earlier beliefs, it is now known that the nearly as many women have ADHD in adulthood with a male-female prevalence of 1.6: to 1. The condition can be detrimental to many areas of life including work, daily activities, social and family relationships and psychological and physical well-being.
Appropriate treatment of ADHD in adults can provide dramatic symptomatic improvement with some of the largest treatment effects of any medical condition.
Recognition and treatment of adult ADHD is important, especially because of the potential for dramatic symptomatic improvement. However, the condition is underdiagnosed and undertreated in practice.
This activity utilizes a flipped classroom design. This begins with a foundational self-study followed by an online live webinar, which will be available on-demand after the live event, where all participants will have the opportunity to interact with the faculty and other learners. This provides an opportunity to discuss more specific management questions and strategies of care.
DISCLOSURE POLICY STATEMENT:
It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
Faculty
Gregg Mattingly, MD serves as a Speaker for Allergan, Lundbeck, Merck, Otsuka, Shire, Sunovion, Takeda and Vanda. Dr. Mattingly also serves as a consultant for Alkermes, Allergan, Forum, Lundbeck, Merck, Otsuka, Perdue, Rhodes, Shire, Sunovion, Takeda and Vanda. Additionally, he serves as a researcher for Akili, Alcobra, Alkermes, Allergan, Boehringer, Forum, Janssen, Medgenics, NLS-1 Pharma AG, Reckitt Benckiser, Shire, Sunovion, Supernus and Takeda.
Planning Committee
Gregg Sherman, MD has no real or apparent conflicts of interest to report.
Harvey Parker, PhD has no real or apparent conflicts of interest to report.
Joshua Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE:
NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.
ACCREDITATION STATEMENT:
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education is also approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222.
This CME activity was planned and produced in accordance with the ACCME Essentials and the AANP CE Standards and Policies and AANP Commercial Support Standards.
For CME questions, please contact: NACE at info@naceonline.com.
Contact this CME provider for privacy and confidentiality policy statement information at: http://www.naceonline.com/privacy_policy.php.
CREDIT DESIGNATION STATEMENT:
The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education (which includes 0.25 hours of pharmacology).
TO OBTAIN CME CREDITS:
- Read the learning objectives and front matter.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- You must score 60% or higher on the post-test to receive credit for this activity.
- Physicians who successfully complete the post-test and evaluation will receive AMA PRA Category 1 credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE FORMAT/MEDIUM: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 60 minutes
ACKNOWLEDGEMENT:
This activity is provided by The National Association for Continuing Education.
Supported by an educational grant from Shire.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
